Phillip A. Sharp - Jun 1, 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Director
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Jun 1, 2022
Transactions value $
$0
Form type
4
Date filed
6/2/2022, 07:08 PM
Previous filing
May 25, 2022
Next filing
Aug 17, 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Remarks:

Exhibit 24: Power of Attorney